ArticleCancer management and research2026
Oncolytic Vaccinia Virus-Engineered EVs Convert Tumor-Promoting Macrophages into Anti-Tumor Effectors.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracellular vesicles (EVs) play a critical role in shaping the tumor immune microenvironment (TME) by mediating intercellular communication and transferring oncogenic proteins, microRNAs, and immunosuppressive molecules. Tumor-derived EVs (TDEVs) typically promote immune evasion by inducing M2 macrophage polarization, suppressing cytotoxic T-cell activity, and enhancing angiogenesis. Recent evidence suggests that oncolytic viruses (OVs) can reprogram EV secretion, generating OV-derived EVs (OV-EVs) with immunostimulatory properties capable of activating antitumor immune responses. Methods: In this study, we investigated how infection with oncolytic vaccinia virus (OVV) alters the EV secretion profile of colon cancer cells. EVs derived from OVV-infected tumor cells were isolated and characterized, and their effects on macrophage polarization were evaluated using in vitro assays. Results: Our results demonstrate that OVV infection significantly alters the composition and immunological properties of tumor-derived EVs. OV-EVs were enriched with pathogen-associated and damage-associated molecular patterns (PAMPs/DAMPs), which promoted macrophage reprogramming toward a pro-inflammatory M1 phenotype and enhanced immune activation associated with antitumor responses. Discussion: These findings indicate that OVV-induced EVs can reshape the tumor immune microenvironment by modulating macrophage polarization. This study provides new insights into the EV-mediated mechanisms of oncolytic virotherapy and highlights the potential of OV-derived EVs as a novel strategy for EV-based cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.